Evaluation of antibiotic use in coronavirus (COVID-19) hospitalised patients

Conditions

COVID-19 (SARS-CoV-2 infection), COVID-19 hospitalised patients Infections and Infestations COVID-19 (SARS-CoV-2 infection), COVID-19 hospitalised patients

Josie Henley, Lucy Brookes‐Howell, Philip Howard, Neil Powell, Mahableshwar Albur et al. (26 authors)

BMJ Open2025-08-01

10.1136/bmjopen-2024-093210

A retrospective propensity-score-matched cohort study of the impact of procalcitonin testing on antibiotic use in hospitalized patients during the first wave of COVID-19

Jonathan Sandoe, Detelina Grozeva, Mahableshwar Albur, Stuart Bond, Lucy Brookes‐Howell et al. (30 authors)

Journal of Antimicrobial Chemotherapy2024-09-092 citations

10.1093/jac/dkae246

Developing a model for decision-making around antibiotic prescribing for patients with COVID-19 pneumonia in acute NHS hospitals during the first wave of the COVID-19 pandemic: qualitative results from the Procalcitonin Evaluation of Antibiotic use in COVID-19 Hospitalised patients (PEACH Study)

Josie Henley, Lucy Brookes‐Howell, Joanne Euden, Philip Pallmann, Martin Llewelyn et al. (18 authors)

BMJ Open2023-12-013 citations

10.1136/bmjopen-2023-077117

Interventions

PEACH will assess whether the use of procalcitonin (PCT) testing, to guide antibiotic prescribing, safely reduced antibiotic use among patients who were hospitalised with COVID-19 during the first wav

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Trust-level clinical data: 1. NHS hospital trust caring for COVID-19 inpatients aged >16 years Patient-level clinical data: 1. Confirmed COVID-19 infection 2. Admitted to participating trust for any reason

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

Measure	Time frame
Current primary outcome measure as of 13/09/2022: 1. Change in level and/or trend of antibiotic prescribing rates following the introduction of PCT testing. Measures using the weekly trend of the number of defined daily doses (DDDs) of prespecified antibiotics commonly used for respiratory tract infection (‘CAP-DDD’) per number of COVID+ admissions collected by Rx Info Ltd, Public Health England, and Public Health Wales between 01/03/2020 and 30/06/2022 2. Length of early antibiotics therapy measured using patient-level data collected within the first 7 days of admission 3. Patient-level cost of illness from COVID-19 in NHS trusts measured using data gathered by Rx Info Ltd, Public Health England, and Public Health Wales at baseline and during the first 7 days of admission 4. Identifying and reviewing published evidence of cost-effectiveness 5. Cost-effectiveness of different PCT testing strategies in COVID-19 Previous primary outcome measure: 1. Antibiotic prescribing rates following the introduction of procalcitonin (PCT) testing measured using the number of defined daily doses (DDDs) of prespecified antibiotics commonly used for respiratory tract infection (CAP-DDD) per number of COVID+ hospital admissions collected by Rx Info Ltd, Public Health England, and Public Health Wales between 01/03/2020 to 30/06/2020 2. Length of early antibiotics therapy measured using patient-level data collected within the first 7 days of admission 3. Patient-level cost of illness from COVID-19 in NHS trusts measured using data gathered by Rx Info Ltd, Public Health England, and Public Health Wales at baseline and during the first 7 days of admission	—

Measure

Time frame

Current primary outcome measure as of 13/09/2022: 1. Change in level and/or trend of antibiotic prescribing rates following the introduction of PCT testing. Measures using the weekly trend of the number of defined daily doses (DDDs) of prespecified antibiotics commonly used for respiratory tract infection (‘CAP-DDD’) per number of COVID+ admissions collected by Rx Info Ltd, Public Health England, and Public Health Wales between 01/03/2020 and 30/06/2022 2. Length of early antibiotics therapy measured using patient-level data collected within the first 7 days of admission 3. Patient-level cost of illness from COVID-19 in NHS trusts measured using data gathered by Rx Info Ltd, Public Health England, and Public Health Wales at baseline and during the first 7 days of admission 4. Identifying and reviewing published evidence of cost-effectiveness 5. Cost-effectiveness of different PCT testing strategies in COVID-19 Previous primary outcome measure: 1. Antibiotic prescribing rates following the introduction of procalcitonin (PCT) testing measured using the number of defined daily doses (DDDs) of prespecified antibiotics commonly used for respiratory tract infection (CAP-DDD) per number of COVID+ hospital admissions collected by Rx Info Ltd, Public Health England, and Public Health Wales between 01/03/2020 to 30/06/2020 2. Length of early antibiotics therapy measured using patient-level data collected within the first 7 days of admission 3. Patient-level cost of illness from COVID-19 in NHS trusts measured using data gathered by Rx Info Ltd, Public Health England, and Public Health Wales at baseline and during the first 7 days of admission

—

Secondary

Measure	Time frame
Current secondary outcome measures as of 13/09/2022: 1. Number of CAP-DDDs per total number of admissions collected by Rx Info Ltd, Public Health England, and Public Health Wales to calculate weekly trends between 01/03/2020 to 30/06/2020 2. Number of DDDs of all antibiotics (excluding anti TB) total DDDs (tDDDs) per number of COVID+ admissions collected by Rx Info Ltd, Public Health England, and Public Health Wales to calculate weekly trends between 01/03/2020 to 30/06/2020 3. Number of tDDDs per total number of admissions collected by Rx Info Ltd, Public Health England, and Public Health Wales to calculate weekly trends between 01/03/2020 to 30/06/2020 4. Number of CAP-DDDs per total number of patient bed days collected by Rx Info Ltd, Public Health England, and Public Health Wales to calculate weekly trends between 01/03/2020 to 30/06/2020 5. Number of CAP-DDDs per number of COVID+ patient bed days collected by Rx Info Ltd, Public Health England, and Public Health Wales to calculate weekly trends between 01/03/2020 to 30/06/2020 6. Number of tDDDs per total number of patient bed days collected by Rx Info Ltd, Public Health England, and Public Health Wales to calculate weekly trends between 01/03/2020 to 30/06/2020 7. Number of tDDDs per number of COVID+ patient bed days collected by Rx Info Ltd, Public Health England, and Public Health Wales to calculate weekly trends between 01/03/2020 to 30/06/2020 8. Total length of antibiotic treatment measured using patient-level data collected at baseline and during the first 7 days of admission 9. tDDDs of antibiotics measured using patient-level data collected at baseline and during the first 7 days of admission 10. Duration of late antibiotic treatment measured using patient-level data collected at baseline and during the first 7 days of admission 11. DDDs of late antibiotic treatment measured using patient-level data collected at baseline and during the first 7 days of admission 12. DDDs of early antibiotic treatment me	—

Measure

Time frame

Current secondary outcome measures as of 13/09/2022: 1. Number of CAP-DDDs per total number of admissions collected by Rx Info Ltd, Public Health England, and Public Health Wales to calculate weekly trends between 01/03/2020 to 30/06/2020 2. Number of DDDs of all antibiotics (excluding anti TB) total DDDs (tDDDs) per number of COVID+ admissions collected by Rx Info Ltd, Public Health England, and Public Health Wales to calculate weekly trends between 01/03/2020 to 30/06/2020 3. Number of tDDDs per total number of admissions collected by Rx Info Ltd, Public Health England, and Public Health Wales to calculate weekly trends between 01/03/2020 to 30/06/2020 4. Number of CAP-DDDs per total number of patient bed days collected by Rx Info Ltd, Public Health England, and Public Health Wales to calculate weekly trends between 01/03/2020 to 30/06/2020 5. Number of CAP-DDDs per number of COVID+ patient bed days collected by Rx Info Ltd, Public Health England, and Public Health Wales to calculate weekly trends between 01/03/2020 to 30/06/2020 6. Number of tDDDs per total number of patient bed days collected by Rx Info Ltd, Public Health England, and Public Health Wales to calculate weekly trends between 01/03/2020 to 30/06/2020 7. Number of tDDDs per number of COVID+ patient bed days collected by Rx Info Ltd, Public Health England, and Public Health Wales to calculate weekly trends between 01/03/2020 to 30/06/2020 8. Total length of antibiotic treatment measured using patient-level data collected at baseline and during the first 7 days of admission 9. tDDDs of antibiotics measured using patient-level data collected at baseline and during the first 7 days of admission 10. Duration of late antibiotic treatment measured using patient-level data collected at baseline and during the first 7 days of admission 11. DDDs of late antibiotic treatment measured using patient-level data collected at baseline and during the first 7 days of admission 12. DDDs of early antibiotic treatment me

—

Countries

England, United Kingdom, Wales

Contacts

Public ContactJoanne Euden

EudenJ@cardiff.ac.ukNo telephone contact provided

Outcome results

None listed